Patient and treatment characteristics
| Characteristic . | HL patients . | |||||
|---|---|---|---|---|---|---|
| Without cardiac events (n = 1092) . | With cardiac events (n = 187) . | Total (N = 1279) . | ||||
| n . | % . | n . | % . | n . | % . | |
| Sex | ||||||
| Female | 524 | 48.0 | 70 | 37.4 | 594 | 46.4 |
| Male | 568 | 52.0 | 117 | 62.6 | 685 | 53.6 |
| Age at diagnosis, y | ||||||
| Median (range) | 25 (3-93) | 29 (5-75) | 25 (3-93) | |||
| < 20 | 325 | 29.8 | 36 | 19.3 | 361 | 28.2 |
| 20-29 | 400 | 36.6 | 60 | 32.1 | 460 | 36 |
| 30-39 | 216 | 19.8 | 35 | 18.7 | 251 | 19.6 |
| 40-49 | 79 | 7.2 | 26 | 13.9 | 105 | 8.2 |
| ≥ 50 | 72 | 6.6 | 30 | 16 | 102 | 8 |
| Median age at cardiac events, y (range) | N/A | 47 (14-87) | N/A | |||
| Clinical stage | ||||||
| I | 240 | 22.0 | 45 | 24.1 | 285 | 22.3 |
| II | 694 | 63.6 | 115 | 61.5 | 809 | 63.3 |
| III | 110 | 10.1 | 25 | 13.4 | 135 | 10.6 |
| IV | 48 | 4.4 | 2 | 1.1 | 50 | 3.9 |
| Follow-up, y | ||||||
| Median (interquartile range) | 13.5 (17.5-19.7) | 21.4 (15-27.7) | 14.7 (8.1-21) | |||
| > 5 | 938 | 85.9 | 180 | 96.3 | 1118 | 87.4 |
| > 10 | 696 | 63.7 | 164 | 87.7 | 860 | 67.2 |
| > 15 | 476 | 43.6 | 140 | 74.9 | 616 | 48.2 |
| Treatment | ||||||
| RT alone | 646 | 59.2 | 134 | 71.7 | 780 | 61.0 |
| RT + chemotherapy | 446 | 40.8 | 53 | 28.3 | 499 | 39.0 |
| Median mediastinal dose, Gy (range) | 40 (15-53) | 40 (15-46) | 40 (15-53) | |||
| RT field | ||||||
| Mantle alone | 357 | 32.7 | 36 | 19.3 | 393 | 30.7 |
| MPA | 594 | 54.4 | 119 | 63.6 | 713 | 55.7 |
| TNI | 93 | 8.5 | 29 | 15.5 | 122 | 9.5 |
| Involved field | 48 | 4.4 | 3 | 1.6 | 51 | 4.0 |
| Doxorubicin | ||||||
| No | 872 | 79.8 | 174 | 93.1 | 1046 | 81.8 |
| Yes | 220 | 20.1 | 13 | 6.9 | 233 | 18.2 |
| Characteristic . | HL patients . | |||||
|---|---|---|---|---|---|---|
| Without cardiac events (n = 1092) . | With cardiac events (n = 187) . | Total (N = 1279) . | ||||
| n . | % . | n . | % . | n . | % . | |
| Sex | ||||||
| Female | 524 | 48.0 | 70 | 37.4 | 594 | 46.4 |
| Male | 568 | 52.0 | 117 | 62.6 | 685 | 53.6 |
| Age at diagnosis, y | ||||||
| Median (range) | 25 (3-93) | 29 (5-75) | 25 (3-93) | |||
| < 20 | 325 | 29.8 | 36 | 19.3 | 361 | 28.2 |
| 20-29 | 400 | 36.6 | 60 | 32.1 | 460 | 36 |
| 30-39 | 216 | 19.8 | 35 | 18.7 | 251 | 19.6 |
| 40-49 | 79 | 7.2 | 26 | 13.9 | 105 | 8.2 |
| ≥ 50 | 72 | 6.6 | 30 | 16 | 102 | 8 |
| Median age at cardiac events, y (range) | N/A | 47 (14-87) | N/A | |||
| Clinical stage | ||||||
| I | 240 | 22.0 | 45 | 24.1 | 285 | 22.3 |
| II | 694 | 63.6 | 115 | 61.5 | 809 | 63.3 |
| III | 110 | 10.1 | 25 | 13.4 | 135 | 10.6 |
| IV | 48 | 4.4 | 2 | 1.1 | 50 | 3.9 |
| Follow-up, y | ||||||
| Median (interquartile range) | 13.5 (17.5-19.7) | 21.4 (15-27.7) | 14.7 (8.1-21) | |||
| > 5 | 938 | 85.9 | 180 | 96.3 | 1118 | 87.4 |
| > 10 | 696 | 63.7 | 164 | 87.7 | 860 | 67.2 |
| > 15 | 476 | 43.6 | 140 | 74.9 | 616 | 48.2 |
| Treatment | ||||||
| RT alone | 646 | 59.2 | 134 | 71.7 | 780 | 61.0 |
| RT + chemotherapy | 446 | 40.8 | 53 | 28.3 | 499 | 39.0 |
| Median mediastinal dose, Gy (range) | 40 (15-53) | 40 (15-46) | 40 (15-53) | |||
| RT field | ||||||
| Mantle alone | 357 | 32.7 | 36 | 19.3 | 393 | 30.7 |
| MPA | 594 | 54.4 | 119 | 63.6 | 713 | 55.7 |
| TNI | 93 | 8.5 | 29 | 15.5 | 122 | 9.5 |
| Involved field | 48 | 4.4 | 3 | 1.6 | 51 | 4.0 |
| Doxorubicin | ||||||
| No | 872 | 79.8 | 174 | 93.1 | 1046 | 81.8 |
| Yes | 220 | 20.1 | 13 | 6.9 | 233 | 18.2 |
Gy indicates gray; MPA, mantle para-aortic; and TNI, total nodal irradiation.